pharmaceuticals

Global Microbiome Market Report, Trends, Share, Outlook, and Forecast to 2028

May 10, 2022
ID: SR/PH-10
Format:Pdf
Pages:220

Global Microbiome Market By Products (Probiotics, Prebiotics, Medical Foods, Supplements and others), By Application (Therapeutics and Diagnostics), By Disease Type (Obesity, Diabetes, Autoimmune Disorder, Metabolic, Gastrointestinal Disorders, Cancer and other Disease) and By Region (North America, Europe, Asia-Pacific, South America and The Middle East & Africa)-Global Forecast to 2028.

Description

Table Of Contents

Methodology

Request Sample

Description

Microbiome Market Overview

The global microbiome market was valued at USD 1.7 billion in 2021, and it is estimated to reach USD 2.2 billion in 2028 with a CAGR of 7.2% during the forecast period of 2022-2028. Growing gastrointestinal disorders, technological advancements, rising investments in microbiome projects in developing countries, and the lucrative company of market players across the globe are elements responsible for the rapid expansion of the global microbiome market. The growing attention to women’s health drives the global human microbiome market. Market stakeholders expand their services arms by developing innovative and technologically progressive products to gain revenue benefits.

What is Microbiome?

The microbiome is a genetic element of different microorganisms such as bacteria, fungi, protozoa, and viruses present inside and on the human body. The microbiome consists of microbes that are both useful and potentially dangerous. Most are symbiotic, and some are pathogenic (promoting disease) in smaller numbers. In a healthy body, pathogenic and symbiotic microbiota coexist without issues. But dysbiosis occurs if a balance is disrupted—brought on by infectious illnesses, certain diets, or the prolonged use of antibiotics or other bacteria-destroying medications—stopping these normal interactions. As a result, the body may become more susceptible to disease.

Growth Drivers

Increasing Prevalence of Gastrointestinal and Metabolic Conditions Push Microbiome Market

The growth of the global microbiome market can be attributed to the increasing prevalence of gastrointestinal & metabolic disorders. The rising awareness about the severity of chronic diseases such as cancer-driving expands the global microbiome market. Major market performers in the microbiome diagnostics segment are launching innovative products to cure several common gut problems, including Crohn’s disease and ulcerative colitis. The segment’s growth can be characterized by the high number of microbiome diagnostic companies and the ease of non-invasive testing delivered by this method.

Growth in Industry-Institute Partnerships and High Unmet Medical Needs to Drive Global Market

Many microbiome therapeutics and diagnostics are targeted toward a market with enormous unmet medical requirements. For example, the current standard of care for Clostridium difficile infection (CDI) is a treatment with antibiotics. Antibiotic treatment can determine acute infection; regardless, it also has the possibility of worsening dysbiosis in patients. It makes them potentially more sensitive to the recurrence of CDI. Patients with recurrent CDI accept many rounds of antibiotics that could worsen dysbiosis and are more likely to face a relapse. Key players strive to resolve unmet medical conditions for cancer, CNS disorders, women’s health disorders, skin disorders, and rare diseases through their microbiome-based products.

Opportunities

Advances in Research & Development Activities in Microbiome Market Create Lucrative Opportunities

The microbiome is a genetic component of microorganisms such as bacteria, fungi, protozoa, and viruses, which live inside and on the human body. Manufacturers operating in the global microbiome market are developing diagnostic and therapeutic products. The increasing research & development activities in the microbiome market contribute to the growth of the global microbiome market.

Technological improvements in metagenomics and next-generation sequencing have made microbiome-based testing simple and cost-effective, paving the way to rapidly examining the genomic content of microorganisms from human samples. It has supported the development process for microbiome-based diagnostics. Gastrointestinal and metabolic conditions are likely to capture the leading share of the diagnostics market due to the advancement in the focus of companies toward developing a comfortable research platform for gut health-based diseases, such as irritable bowel syndrome and Crohn’s condition. Rising actions by manufacturers to create non-invasive tests create potential opportunities for market growth.

Restraints

Obstacles to proving the causal connection between dysbiosis and diseases

The human body is home to various communities of symbiotic, commensal, and pathogenic microorganisms, collectively understood as the microbiota. Different studies also indicated that only 30-40 species share the bulk of microbiota among people. Researching specific bacteria from among trillions of species can be highly problematic. High-throughput omics technologies can determine the identical bacterial species involved and understand how homeostasis between humans and microbes is supported. According to microbiome research, microbiome dysbiosis results in multiple chronic and lifestyle diseases, such as obesity, diabetes, and various digestive disorders.

The current methods for determining microbial markers for diagnostic objectives depend on comparisons with similar control groups of healthy individuals. Choosing the correct microbial chassis for a microbiota-based therapeutic is challenging as indicating which microbe is best suited for any application.

Pre Covid-19 Impact on Global Microbiome Market

Before the covid-19 period, many human medical conditions, such as inflammatory bowel diseases and obesity, were closely connected with the composition of the gut microbial community; also, conditions such as asthma and diabetes are thought to be impacting this microbial community. Many measures are being taken to alter the gut microbiome to eradicate different diseases. Probiotics, prebiotics, dietary supplements, and foods that include live microbes have been studied thoroughly to assess their effects on human health, increasing the microbiome market’s growth.

Covid-19 Impact on Global Microbiome Market

During the Covid-19 period, the pandemic has created massive disruptions to clinical trial research worldwide. As in other parts of life, the virus has severely impacted the ability to conduct trials in safe and effective ways. It is especially true when considering that trials often deal with vulnerable populations most at threat from exposure to covid-19. Seres Therapeutics’ SER-287 development action was adversely impacted by the pandemic and multiple clinical sites halting non-essential procedures, including endoscopies. Similarly, covid-19 has adversely affected and could continue to impact other companies’ businesses, including their preclinical investigations and clinical trials of microbiome-based therapeutics and diagnostic products.

Post Covid-19 Impact on Global Microbiome Market

After the covid-19 period, this technical and expertise-oriented industry research report scrutinizes the Microbiome therapeutics industry’s technical and commercial business outlook. The report analyzes and declares the historical and current trends analysis of the microbiome therapeutics industry and subsequently recommends the projected trends observed in the microbiome therapeutics market during the upcoming years. Other key factors pushing the growth of this market are the increasing burden of lifestyle-related diseases and the growing senior population. Lowering the level of microbiota will increase the growth of fatal infectious diseases and organisms.

By Application Segmental Analysis

Based on the application segment, the global microbiome market is segmented into Therapeutics and Diagnostics. The therapeutics segment holds the largest share of the microbiome market. The upsurge in funding for R&D into microbiome-based therapies worldwide is the primary aspect pushing the growth of this application segment. In addition, technological improvements, the increasing number of clinical trials for the diagnostics segment, and expanding partnerships between key market participants and research institutes also help market growth.

By Disease Type Segmental Analysis

Based on Disease Type, the global microbiome market is segmented into Obesity, Diabetes, Autoimmune Disorder, Metabolic, Gastrointestinal Disorders, Cancer and other diseases. The infectious disease segment is anticipated to register the highest growth rate during the forecast period. Increasing cognizance of the ill outcomes of antibiotic use on the natural flora (such as disruptions) has highlighted the demand for specific bacterial-targeted therapy for infectious diseases. The rising incidence of infections due to microbial dysbiosis due to antibiotic treatment and the increasing number of clinical practices for developing target-specific microbiome-based therapies are the major factors driving the growth of this segment.

By Regional Segmental Analysis

Based on region, the global microbiome market is segmented into North America, Europe, Asia-Pacific, South America and The Middle East & Africa. North America calculated for the largest share of the overall market, followed by Europe. The increasing incidences of lifestyle conditions, rising attention to preventative healthcare, availability of budget for microbiome research, and the growing number of microbiome research & clinical activities are pushing the market’s growth in North America.

Competitors Analysis

The companies include Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome, Kallyope, Finch Therapeutics, Concentric, AOBiome, Enterome, Metabiomics Corporate and other prominent players in the global microbiome market.

Key Stakeholders

Recent Developments

In 2022- OptiBiotix Health Plc. Contracted an exclusive sales and distribution agreement with Nahdi Medical Co., GoFigure, and SlimBiome Medical weight management products will be unrestricted in the KSA from early 2022 through the new agreement with Nahdi.
In 2020-4D, pharma connected with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will help and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and occurring class of drugs described by the FDA as biological products that include a live organism, such as a bacterium, that applies to the deterrence, treatment, or treatment of a disease.
In 2019- Series collaborated with AstraZeneca to better understand the microbiome in increasing cancer immunotherapy effectiveness and potential synergy with AstraZeneca compounds.

Scope of the Report

Report Attribute	Details
Revenue in 2021	USD 1.7 billion
The revenue forecast in 2028	USD 2.2 billion
Growth rate	CAGR of 7.2% from 2022 to 2028.
Historical data	2017 – 2020
Base Year	2021
Forecast period	2022 – 2028
Region covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	The companies Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome, Kallyope, Finch Therapeutics, Concentric, AOBiome, Enterome and Metabiomics Corporate are the key players.

Market Modelling

By-Products

Probiotics
Prebiotics
Medical Foods
Supplements
Others

By Application

Therapeutics
Diagnostics

By Disease Type

By Region

North America
Europe
Asia Pacific
South America
The Middle East & Africa

More Related Reports:

Cytokines Market

AI in Aerospace Market

Smart Airports Market

Middle East Cyber Security Market

Embedded Boards & Modules Market

Variable Frequency Drive Market

Real Estate Crowdfunding Market

Onshore Oil and Gas Pipeline Market

Southeast Asia Secondary Surveillance Radar Market

Global Gaming Peripherals Market

Table Of Contents

Methodology

Request Sample

Frequently Asked Questions (FAQ):

What is the market size of the global microbiome market?

The global microbiome market was valued at USD 1.7 billion in 2021, and it is estimated to reach USD 2.2 billion in 2028 with a CAGR of 7.2% during the forecast period of 2022-2028.

What are the growth drivers in the global microbiome market?

The increasing prevalence of gastrointestinal and metabolic conditions to push the microbiome market, growth in industry-institute partnership and high unmet medical needs to drive the global market are two of the main growth drivers in the global microbiome market.

Who are the key players in the global microbiome market?

The companies Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome, Kallyope, Finch Therapeutics, Concentric, AOBiome, Enterome and Metabiomics Corporate are the key players.

What are the growth opportunities in the global microbiome market?

The increasing prevalence of gastrointestinal and metabolic conditions pushes Microbiome Market and growth in Industry-Institute partnerships and high Medical Needs to drive the Global Market.

Which region has the largest share in the global microbiome market?

North America calculated for the largest share of the microbiome market, followed by Europe.

Select License

We Accept

Analyst support

After evaluating your requirements and addressing your technical problems, the expert analyst will resolve your query directly.

Customer satisfaction

According to your needs, our expert team will assist you with the capabilities, services, and proper research needs to be required and customize the report accordingly.

Inimitable expertise

Our expert team will create unrivaled reviews to provide you with a deep understanding of the reports.

Assured quality

We have created a systematic way to determine standards and satisfy your expectations.

Instant delivery

Unlike others, we provide you a great deal of instant delivery in the form of PDF/PPT/Word Doc directly to your email address within 24 hours after receiving full payment.

Privacy policy

We understand the inkling of your privacy, we will never misuse your email address.

Custom research service

We are giving you an opportunity through which you can directly ask our expert analyst to customize an exclusive study of the report to serve your research needs.

Quality & accuracy

We provide you with the accurate quality of the customized study of an exclusive report according to your research need.

Data visualization

As the business world’s growing faster every day, we understand the value of data management. We will create the reports by keeping all the visual data sets and metrics in the charts.

Information security

We truly respect your privacy and promise to keep your personal and confidential information safe and secure.

Global Microbiome Market Report, Trends, Share, Outlook, and Forecast to 2028

Microbiome Market Overview

What is Microbiome?

Growth Drivers

Increasing Prevalence of Gastrointestinal and Metabolic Conditions Push Microbiome Market

Growth in Industry-Institute Partnerships and High Unmet Medical Needs to Drive Global Market

Opportunities

Advances in Research & Development Activities in Microbiome Market Create Lucrative Opportunities

Restraints

Obstacles to proving the causal connection between dysbiosis and diseases

Pre Covid-19 Impact on Global Microbiome Market

Covid-19 Impact on Global Microbiome Market

Post Covid-19 Impact on Global Microbiome Market

By Application Segmental Analysis

By Disease Type Segmental Analysis

By Regional Segmental Analysis

Competitors Analysis

Recent Developments

Scope of the Report

Market Modelling

More Related Reports:

Report Content

Frequently Asked Questions (FAQ):

Select License

We Accept

Latest Reports

Why Choose Us

Company

Industries We Serve

We Accept

Contact Info